Related Experiment Video

Updated: Jun 27, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K

Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma

Danai Samutpradit1, Phurin Areesawangkit1, Pranaidej Hengswat1

  • 1Siriraj Center of Research Excellence for Cancer Immunotherapy and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Anticancer Research
|December 30, 2025
PubMed
Abstract

Insights

This study shows that a novel dendritic cell therapy targeting NY-ESO-1 can activate T-cells to fight multiple myeloma (MM). This approach enhances anti-tumor activity against NY-ESO-1-positive MM cells.

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Biology

Background:

  • Multiple myeloma (MM) is an incurable blood cancer characterized by relapse and treatment resistance.
  • Cancer-testis antigen NY-ESO-1 presents a potential target for T-cell-based immunotherapy in MM.
  • The efficacy of NY-ESO-1 as an immunotherapeutic target requires further investigation.

Purpose of the Study:

  • To evaluate NY-ESO-1 as a target for T-cell immunotherapy in MM.
  • To assess the potential of a self-differentiated monocyte-derived dendritic cell platform (SD-DC-NY) for activating T-lymphocytes against MM.
  • To investigate the in vitro anti-tumor activity of SD-DC-NY-activated T-lymphocytes against MM cells.

Main Methods:

  • NY-ESO-1 expression was analyzed in 95 MM samples using immunohistochemistry (IHC).
  • A lentiviral construct encoding GM-CSF, IL-4, and NY-ESO-1 was used to generate SD-DC-NY.
  • Autologous T-lymphocytes were activated with SD-DC-NY and tested against NY-ESO-1-positive (U266) and negative (JJN-3) MM cells, measuring cytotoxicity and IFN-γ secretion.

Main Results:

  • NY-ESO-1 was detected in 17.9% of MM cases.
  • SD-DC-NY demonstrated comparable DC maturation to conventional DCs.
  • SD-DC-NY-activated T-lymphocytes significantly increased apoptosis in U266 cells (p<0.0001) and enhanced IFN-γ secretion (p<0.05).

Conclusions:

  • SD-DC-NY effectively primes cytotoxic T-lymphocytes against MM.
  • The platform enhances anti-tumor activity in NY-ESO-1-positive MM cells.
  • NY-ESO-1 is a viable immunotherapeutic target, and SD-DC-NY shows promise for MM immunotherapy.
Keywords:
NY-ESO-1SD-DCSelf-differentiated dendritic cellsadoptive T cell therapymultiple myeloma

More Related Videos

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...